ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "interstitial lung disease"

  • Abstract Number: 1231 • ACR Convergence 2022

    [68Ga]- CPCR4 Trifluoroacetate PET/CT Imaging of Chemokine Receptor CXCR4- Expression in Systemic Sclerosis Related Interstitial Lung Disease

    Chirag Rajkumar Kopp1, Shefali Sharma2, Venkata Subramanian Krishnaraju3, Chandra Bhushan Prasad3, Jagdeep Singh3, Shashi Anand3, Ranjana Minz3, Ashwani Sood3, Anindita Sinha3, Rajender Kumar Basher3, Sahajal Dhooria3, Varun Dhir4 and sanjay jain3, 1Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2PGIMER< Chandigarh, Chandigarh, India, 3Postgraduate Institute of Medical Education and Research, Chandigarh, India, 4PGIMER, CHD, INDIA, Chandigarh, India

    Background/Purpose: Interstitial lung disease (ILD) in Systemic sclerosis (SSc) is a major contributor of morbidity and mortality. CXCR4/CXCL12 axis has been implicated in the pathogenesis…
  • Abstract Number: 1855 • ACR Convergence 2022

    Clinical Outcomes in an Observational Retrospective Cohort of Patients with Connective Tissue Disease-associated Interstitial Lung Disease (CTD-ILD) Who Taper Immunosuppressive Therapy

    Paul Dellaripa, Paul Hoover and Tracy Doyle, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Patients with CTD-ILD are often treated with a combination of corticosteroids and steroid sparing agents to limit the progression of the inflammatory response in…
  • Abstract Number: 2250 • ACR Convergence 2022

    Genetic and Environmental Risk Factors in Rheumatoid Arthritis-Associated Interstitial Lung Disease

    Austin Wheeler1, Yangyuna Yang1, Joshua Baker2, Jill Poole1, Dana Ascherman3, Gail Kerr4, Andreas Reimold5, Gary Kunkel6, Grant Cannon7, Katherine Wysham8, Namrata Singh9, Deana Lazaro10, Paul Monach11, S. Louis Bridges, Jr.12, Ted Mikuls13 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pennsylvania, Philadelphia, PA, 3University of Pittsburgh, Pittsburgh, PA, 4Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 5University of Texas Southwestern Medical Center, Dallas, TX, 6University of Utah, Salt Lake City, UT, 7Retired, Salt Lake City, UT, 8VA Puget Sound/University of Washington, Seattle, WA, 9University of Washington, Bellevue, WA, 10VA New York Harbor Healthcare system, Short Hills, NJ, 11VA Boston Healthcare System, Boston, MA, 12Hospital for Special Surgery, New York, NY, 13Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: RA-associated interstitial lung disease (RA-ILD) is an extra-articular manifestation of RA causing substantial morbidity and mortality. Genetic risk variants, such as the MUC5B rs35705950…
  • Abstract Number: 0248 • ACR Convergence 2022

    Monocyte Chemoattractant Protein-1, Vascular Cell Adhesion Protein-1 and Asymmetric Dimethylarginine as Potential Biomarkers of Interstitial Lung Disease Associated with RA

    Veronica Pulito-Cueto1, Sara Remuzgo-Martinez1, Fernanda Genre1, Belén Atienza-Mateo1, Víctor M. Mora-Cuesta1, David Iturbe-Fernández1, Leticia Lera-Gómez1, Diana Prieto-Peña1, Virgi Portilla1, Ricardo Blanco2, Alfonso Corrales1, Oreste Gualillo3, José M. Cifrián1, Raquel Lopez Mejias4 and Miguel Ángel González-Gay5, 1Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 2Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, 3Hospital Clínico Universitario de Santiago, SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), NEIRID Lab (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Research Laboratory 9, Santiago de Compostela, Spain, 4IDIVAL, Santander, Spain, 5Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

    Background/Purpose: Interstitial lung disease (ILD) is one of the main comorbidities of patients with RA contributing to an increased mortality risk [1]. The pathogenesis of…
  • Abstract Number: 1047 • ACR Convergence 2022

    A Novel Prediction Tool for Progression of Systemic Sclerosis-Interstitial Lung Disease Despite Treatment with Immunosuppression

    Elizabeth Volkmann1, Holly Wilhalme1, Grace Kim1, Jonathan Goldin1, Shervin Assassi2, Masataka Kuwana3, Donald Tashkin1 and Michael roth1, 1University of California Los Angeles, Los Angeles, CA, 2McGovern Medical School, University of Texas, Houston, TX, 3Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Systemic sclerosis-interstitial lung disease (SSc-ILD) is the leading cause of SSc-related death. While some patients respond favorably to treatment with immunosuppression, a subset of…
  • Abstract Number: 1246 • ACR Convergence 2022

    Improving Radiologic Interpretation of Diffuse Lung Disease in Pediatric Rheumatologic (PR) Patients Using Trained Scoring with Semi-quantitative Chest Computed Tomography (CT) Analysis

    Michal Cidon1, Beverley Newman2, Terry Robinson3, Paul Iskander4, Paul Thacker5, Evan Zucker2, Tzielan Lee6 and Rex Moats3, 1Children's Hospital Los Angeles, Los Angeles, CA, 2Stanford Children's Health, Stanford, CA, 3Children's Hospital of Los Angeles, Los Angeles, CA, 4University of California Los Angeles, Los Angeles, CA, 5Mayo Clinic, Rochester, MN, 6Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: We presented preliminary data in 2021 to support the feasibility of using a semi-quantitative chest CT scoring system (Pediatric Rheumatologic Diffuse Lung Disease Score…
  • Abstract Number: 1857 • ACR Convergence 2022

    Increasing Proportion of MDA-5 Associated Conditions in a Tertiary Myositis Centre Following Onset of the Covid-19 Pandemic

    Jennifer Hannah1, Saadia Sasha Ali1, Sloni Arora1, John Cazabon1, James Galloway1 and Patrick Gordon2, 1King's College London, London, United Kingdom, 2King’s College Hospital NHS Foundation Trust, London, United Kingdom

    Background/Purpose: Anti-MDA5 dermatomyositis is a clinical subtype of DM that is strongly associated with a rapidly progressive phenotype of interstitial lung disease resulting in a…
  • Abstract Number: 2251 • ACR Convergence 2022

    Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

    Matthew Baker1, Yuhan Liu1, Rong Lu1, Janice Lin1, Jason Melehani1 and William Robinson2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
  • Abstract Number: 0249 • ACR Convergence 2022

    Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

    Jill Poole1, Bryant England1, Kathryn Cole1, James Talmadge1, Amy Nelson1, Rohit Gaurav1, Aaron Schwabb1, Angela Gleason1, Michael Duryee1, Rhonda Walenz1, Bridget Kramer1, Joel VanDeGraaff1, Sara May1, Geoffrey Thiele1 and Ted Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Interstitial lung disease (ILD) is associated with significant morbidity and mortality in rheumatoid arthritis (RA). The key cellular players of RA-ILD remain largely unknown.…
  • Abstract Number: 1048 • ACR Convergence 2022

    Nailfold Capillaroscopy and Candidate Biomarker Levels in Systemic Sclerosis-associated Pulmonary Hypertension, Profiling of Non-invasive Markers: A Cross Sectional Study

    Jacqueline Lemmers1, Arjan van Caam2, Brigit Kersten2, Els Ende, van den2, Hanneke KNAAPEN2, Arie Dijk, van2, Wanda Hagmolen of ten Have2, Frank van den Hoogen2, Hans Koenen2, Sander van Leuven3, wynand Alkema4, Ruben Smeets2 and Madelon Vonk5, 1Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands, 2Radboudumc, Nijmegen, Netherlands, 3Radboud University, Nijmegen, Netherlands, 4Hanze University, Groningen the Netherlands, Dept. Data Science for Life Sciences & Health, Groningen, Netherlands, 5Department of Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands

    Background/Purpose: Pulmonary hypertension (PH) is one of the leading causes of death in Systemic Sclerosis (SSc). Early detection and treatment of PH in SSc is…
  • Abstract Number: 1247 • ACR Convergence 2022

    Lung Ultrasound in Patients with Connective Tissue Disease-associated Interstitial Lung Disease; Utility of Single Evaluation in Clinical Practice

    Shinji Watanabe1, Keina Yomono2, Mikito Suzuki2, Nobuhito Sasaki2, Takahisa Gono2 and Masataka Kuwana2, 1Nippon Medical School Graduate School of Medicine, Bunkyo-ku, Tokyo, Japan, 2Nippon Medical School Graduate School of Medicine, Tokyo, Japan

    Background/Purpose: Utility of lung ultrasound (LUS) in evaluation of interstitial lung disease (ILD) has recently attracted attention because of handiness and low invasiveness. The majority…
  • Abstract Number: 1858 • ACR Convergence 2022

    A Multi-center Clinical Cohort Study of Chinese Anti-synthetase Syndrome Patients

    mingwei tang1, Qian Wang1, wei Wei2, Pingting Yang3, Xinwang Duan4, Hongbin Li5, Chanyuan Wu6, JIULIANG ZHAO7, jia shi1, Xiaomei Leng8, Xinping Tian1, MENGTAO LI9, Yan Zhao1 and Xiaofeng Zeng10, 1Peking Union Medical College Hospital, Beijing, China, 2Tianjin Medical University General Hospital, Tianjin, China, 3The First Hospital of China Medical University, Shenyang, China, 4the Second Affiliated Hospital of Nanchang University, Nanchang, China, 5Inner Mongolia Medical University, Hohhot City, China, 6Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China, 7Beijing Union Medical College Hospital, Beijing, China, 8Peking Union Medical College Hospital, Department of Rheumatology and Clinical Immunology, Beijing, China, 9Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, State Key Laboratory of Complex Severe and Rare Diseases, Ministry of Science & Technology, Beijing, China, 10Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China

    Background/Purpose: Based on the Chinese Rheumatology Data Center Inflammatory Myopathy Registry (CRDC-MYO), this study aimed to describe the baseline characteristics of a subgroup of patients…
  • Abstract Number: 2252 • ACR Convergence 2022

    Higher Matrix Metalloproteinase Levels Are Predictive of Incident Interstitial Lung Disease Among a Cohort of US Veterans with Rheumatoid Arthritis

    Brent Luedders1, Dana Ascherman2, Joshua Baker3, Michael Duryee1, Yangyuna Yang1, Punyasha Roul4, Katherine Wysham5, Paul Monach6, Andreas Reimold7, Gail Kerr8, Gary Kunkel9, Grant Cannon10, Jill Poole1, Geoffrey Thiele1, Ted Mikuls11 and Bryant England1, 1University of Nebraska Medical Center, Omaha, NE, 2University of Pittsburgh, Pittsburgh, PA, 3University of Pennsylvania, Philadelphia, PA, 4UNMC, Omaha, NE, 5VA Puget Sound/University of Washington, Seattle, WA, 6VA Boston Healthcare System, Boston, MA, 7University of Texas Southwestern Medical Center, Dallas, TX, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9University of Utah, Salt Lake City, UT, 10Retired, Salt Lake City, UT, 11Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Matrix metalloproteinases (MMPs) degrade extracellular matrix and have been implicated to play a role in a number of fibrotic processes. Specifically, MMPs have been…
  • Abstract Number: 0258 • ACR Convergence 2022

    Rheumatoid Arthritis Associated Interstitial Lung Disease Across Continents

    Sascha Heckert1, Tjardo Maarseveen2, Emiel Marges2, Arvind Chopra3, David Vega Morales4, Riette Du Toit5, Annette van der Helm-van Mil6, Tom Huizinga2, CF Allaart2 and Sytske Anne Bergstra7, 1Leiden University Medical Centre, Leiden, Netherlands, 2Leiden University Medical Center, Leiden, Netherlands, 3Center for Rheumatic Diseases, Pune, Maharashtra, India, 4Hospital General de Zona 17, Instituto Mexicano del Seguro Social, Monterrey, Mexico, 5Stellenbosch University and Tygerberg Academic Hospital, Cape Town, South Africa, 6Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, 7LUMC, Leiden, Netherlands

    Background/Purpose: Interstitial lung disease (ILD) is a spectrum of inflammatory and fibrotic lung diseases, and can be associated with RA (RA-ILD). The reported prevalence in…
  • Abstract Number: 1058 • ACR Convergence 2022

    Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis

    Jessica Fairley1, Dylan Hansen2, Laura Ross3, Susanna Proudman4, Jo Sahhar5, Gene-Siew Ngian6, Jenny Walker7, Lauren Host8, Kathleen Morrisroe2, Diane Apostolopoulos9, Nava Ferdowsi2, Michelle Wilson9, Maryam Tabesh2, Wendy Stevens2 and Mandana Nikpour10, 1The University of Melbourne, Melbourne, Australia, 2St Vincent's Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 4University of Adelaide, Medindie, Australia, 5Monash Health, Melbourne, Australia, 6Melbourne Health, Northcote, Australia, 7Royal Adelaide Hospital, Adelaide, Australia, 8Fiona Stanley Hospital, London, United Kingdom, 9Monash University, Melbourne, Australia, 10The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • 21
  • …
  • 39
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology